Benralizumab shows encouraging results in hypereosinophilic syndromes |
Clinical News
eMediNexus Coverage from: 
Benralizumab shows encouraging results in hypereosinophilic syndromes

0 Read Comments                

Benralizumab used to treat a severe form of asthma dramatically improved the health of people with rare chronic immune disorders called hypereosinophilic syndromes (HES) in whom other treatments were ineffective or intolerable in a small clinical trial of 20 people with severe forms of HES who had at least 1,000 eosinophils/µL of blood at baseline and whose condition had been stable on other HES therapies for at least a month before enrolling.At the start of the first phase, which lasted 12 weeks, study participants were assigned at random to receive either 30 mg of benralizumab or a placebo solution through an injection under the skin once every 4 weeks while continuing to take their current HES therapy. Neither the participants nor the investigators knew who was receiving the study drug or what the participants’ eosinophil counts were during this first phase.In the second p...
To Read or comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now